Max Gelman
Max Gelman ties clinical data to commercial consequence, focusing on how late-stage trial results and regulatory decisions reshape the business prospects of new medicines. He reports on the biopharma industry for Endpoints News, with a core focus on drug pipelines, oncology and other specialty areas where science, strategy and market pressure meet.
Oncology pipelines and pivotal trial readouts
Gelman’s coverage concentrates on late-stage drug development, especially oncology programs that are approaching or entering pivotal trials. He frequently builds stories around fresh efficacy and safety data, explaining trial design, primary endpoints and patient populations in clear terms before turning to what those outcomes mean for a company’s portfolio. Rather than treating a data drop as an isolated milestone, he shows how a Phase 2 or Phase 3 result can shift internal priorities, threaten incumbents or open a new commercial niche. Setbacks receive the same level of attention as wins, with detail on adverse events, pauses or discontinuations and how those problems can ripple through a pipeline or strategy. Across these pieces he keeps a steady focus on the medium-term stakes: competitive positioning, timelines to filing, and how much room is left in a given indication before the field is saturated.
Antibody-drug conjugates and other next-gen modalities
Within oncology, Gelman spends particular time on antibody-drug conjugates and other next-generation modalities that are drawing heavy investment. His reporting on Merck’s antibody-drug conjugate sac-TMT and its first global Phase 3 win, delivered ahead of internal expectations, is a template for his approach: he walks through the clinical result, locates it within an increasingly crowded modality class, and looks at what it means for the company’s broader ambitions in that space. He often treats individual assets as proof points for larger trends, such as how far companies are willing to push dosing, combinations or new tumor types to secure an edge. When he covers emerging technologies beyond ADCs, he uses similar framing, showing how technical choices in trial design and target selection feed directly into business risk, differentiation and potential pricing power.
Big pharma strategy, partnerships and pipeline risk
Although his stories are rooted in clinical programs, Gelman consistently connects those programs to big pharma strategy and business outcomes. He tracks how large companies re-balance their portfolios in response to successes and failures, whether that means doubling down on a mechanism, walking away from a class or reshuffling resources between franchises. Coverage of new readouts routinely includes discussion of looming loss-of-exclusivity cliffs, internal revenue targets or competitive threats that make a given asset more or less central to a company’s future. When collaborations, co-development deals or licensing agreements sit behind a program, he highlights how economics and governance of those relationships shape development decisions. Across this work he treats business risk as multi-dimensional, blending scientific uncertainty, regulatory scrutiny and market dynamics rather than reducing it to a single financial metric.
Fast-turn industry news with technical clarity
Gelman writes primarily in a fast-turn news format, often filing closely against company announcements or major data events. His stories are concise but technically specific, taking the extra step to spell out what a headline result means in practical terms for clinicians, regulators and investors without resorting to boosterish language. He regularly weaves in comments from company executives or external experts to test the strength of the narrative a company is presenting against the underlying data. Even on tight timelines, he avoids treating press releases as standalone sources, instead pressing for context on earlier trial phases, competing programs and what still needs to be proven. The result is coverage that gives industry readers enough scientific and strategic detail to understand why a data point matters, not just that it happened.
4 more business journalists.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex Smith
Alex Smith focuses on the business impact of enterprise technology, with a distinctive emphasis on AI literacy and skills rather than technical specifications. They write for Technology Record, covering how artificial intelligence and cloud platforms from major providers are turned into concrete programmes for organisations and governments. Their beat sits at the junction of business strategy, national digital policy and large-scale technology partnerships. They report on national AI literacy programmes and public–private partnerships, showing how policy choices, vendor capabilities and skills gaps intersect. On the business beat, they treat AI and cloud as tools for competitiveness, workforce readiness and participation in a data-driven economy. Their concise, announcement-led reporting highlights who is partnering with whom, what programme is being launched, which technologies underpin it and how it changes capability on the ground for executive readers.
Alison Durkee
Alison Durkee focuses on how law, regulation and politics create business risks for major companies and industries. She is a reporter at Forbes, where she writes news-driven explainers on complex legal and regulatory developments and their impact on corporate strategy, reputation and markets. Her coverage centers on companies under scrutiny, especially in technology and other high-growth sectors, and tracks trials, investigations and fast-changing policy fights. She breaks down lawsuits, inquiries and regulatory moves into clear parts, grounded in timelines, filings and official actions. She reports on generative artificial intelligence and other emerging technologies as tests of legal frameworks and corporate risk management, explaining how issues like intellectual property, safety compliance, consumer protection and governance can reshape product roadmaps, partnerships and investor expectations.
Alyson Shontell
Alyson Shontell covers business through the lens of leadership, using in-depth conversations with powerful executives and founders to show how their decisions shape companies, markets, and public life. She is editor in chief at Fortune, overseeing coverage across the masthead while continuing to write selected high-impact pieces. Her core work is long, reported interviews and profiles of CEOs of large companies, dominant tech firms, and fast-growing startups. She focuses on how leaders think, manage risk, make unconventional calls, and handle crises, culture, and the future of work. Her subjects include corporate chiefs, startup founders, and political figures treated as executives. She probes operating detail, governance, internal culture, and trade-offs around growth, disruption, and workplace models, using concrete examples and direct, accessible prose that foregrounds the subject’s voice while pressing for specifics.